Evidence map›Paper›PMID 16076020›Full record

ArticleNeurochemical research2005

PRP-1 protective effect against central and peripheral neurodegeneration following n. ischiadicus transection.

Armen A Galoyan, John S Sarkissian, Ruben M Sulkhanyan, Vergine A Chavushyan, Zubeida A Avetisyan, Zaruhi E Avakyan, Anoush J Gevorgyan, Davit O Abrahamyan, Yuri Kh Grigorian

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. αImmunologic research · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Armen A GaloyanBuniatian Institute of Biochemistry NAS RA, 5/1 Sevag str, 375014, Yerevan, Republic of Armenia. galoyan@sci.am
John S Sarkissian
Ruben M Sulkhanyan
Vergine A Chavushyan
Zubeida A Avetisyan
Zaruhi E Avakyan
Anoush J Gevorgyan
Davit O Abrahamyan
Yuri Kh Grigorian

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the action of the new hypothalamic proline-rich peptide (PRP-1), normally produced by neurosecretory cells of hypothalamic nuclei (NPV and NSO), 3 and 4 weeks following rat sciatic nerve transection. The impulse activity flow of interneurons (IN) and motoneurons (MN) on stimulation of mixed (n. ischiadicus), flexor (n. gastrocnemius--G) and extensor (n. peroneus communis--P) nerves of both injured and symmetric intact sides of spinal cord (SC) was recorded in rats with daily administration of PRP-1 (for a period of 3 weeks) and without it (control). On the injured side of SC in control, there were no responses of IN and MN on ipsilateral G and P stimulation, while responses were elicited on contralateral nerve stimulation. The neuron responses on the intact side of SC were revealed in a reverse ratio. Thus, there were no effects upon stimulation of the injured nerve distal stump in the control because of the absence of fusion between transected nerve stumps. This was also testified by the atrophy of the distal stump and the absence of motor activity of the affected limb. In PRP-1-treated animals, the responses of SC IN and MN in postaxotomy 3 weeks on the injured side of SC at ipsilateral nerve stimulation and on the intact side at contralateral nerve stimulation were recorded because of the obvious fusion of the severed nerve stumps. The histochemical data confirmed the electrophysiological findings. Complete coalescence of transected fibers together with restoration of the motor activity of the affected limb provided evidence for reinnervation on the injured side. Thus, it may be concluded that PRP-1 promotes nerve regeneration and may be used clinically to improve the outcome of peripheral nerve primary repair.

Indexed as

Neuroprotective AgentsAlgorithmsAnimalsCentral Nervous SystemElectric StimulationElectrophysiologyFemaleHindlimbMaleNerve FibersNerve RegenerationNeurodegenerative DiseasesPeptidesPeripheral NervesProline-Rich Protein DomainsRatsNeuroprotective AgentsPeptides

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.